Extended-Release Intramuscular Paliperidone Palmitate
- 988 Downloads
Extended-release intramuscular paliperidone palmitate (Xeplion®; Invega® Sustenna®) [henceforth referred to as intramuscular paliperidone palmitate] is a long-acting injectable (LAI) formulation of the well established atypical anti-psychotic agent paliperidone (9-hydroxyrisperidone), which is the major active metabolite of risperidone. This article reviews, from an EU perspective, the therapeutic efficacy and tolerability of intramuscular paliperidone palmitate in the treatment of adults with schizophrenia, and the pharmacology of paliperidone that is relevant to the intramuscular formulation.
Intramuscular paliperidone palmitate 25–150mg equivalents (mg eq.) effectively reduced symptoms of schizophrenia in most short-term (9–13 weeks) placebo-controlled trials, as demonstrated by improvements in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to endpoint that were significantly greater in intramuscular paliperidone palmitate than placebo recipients. The onset of clinical response was 8 days in patients who received the recommended initial 150mg eq. dose of intramuscular paliperidone palmitate into the deltoid muscle on day 1.
In a longer-term (24-week maintenance phase and variable length double-blind phase) placebo-controlled trial, intramuscular paliperidone palmitate was associated with a significantly longer time to relapse than placebo in patients with schizophrenia at a preplanned interim analysis conducted after 68 relapse events. Because of these favourable results, the study was terminated early.
In two 13-week trials, one of which was conducted in Chinese patients, intramuscular paliperidone palmitate administered using the recommended initiation dosage regimen was noninferior to LAI-risperidone in patients with schizophrenia in terms of the between-group treatment difference (intramuscular paliperidone palmitate vs LAI-risperidone) for the mean change from baseline to endpoint in PANSS total score.
The tolerability of intramuscular paliperidone palmitate was generally acceptable in clinical trials of schizophrenia. No new safety concerns were revealed compared with oral paliperidone, except for injection site-related reactions.
In conclusion, intramuscular paliperidone palmitate is a useful option for the treatment of patients with schizophrenia.
KeywordsSchizophrenia Risperidone Antipsychotic Agent Paliperidone Gluteal Muscle
- 1.National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National clinical guideline number 82 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf [Accessed 2012 Jan 20]
- 5.The Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study VIII. Five-year follow-up: clinical and psychosocial findings. Br J Psychiatry 1992 Oct; 161 (4): 496–500Google Scholar
- 9.Janssen-Cilag International NV. Paliperidone palmitate 25, 50, 75, 100, and 150mg prolonged-release suspension for injection (Xeplion®): EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf [Accessed 2011 Oct 6]
- 10.Ortho-McNeil-Janssen Pharmaceuticals. Paliperidone palmitate extended-release injectable suspension for intramuscular use (Invega Sustenna®): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022264s006lbl.pdf [Accessed 2012 Jan 10]
- 11.Janssen-Cilag International NV. Invega® (paliperidone) prolonged-release tablets: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000746/WC500034925.pdf [Accessed 2012 Jan 13]
- 12.Ortho-McNeil-Janssen Pharmaceuticals. Invega® (paliperidone) extended-release tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021999s020s024lbl.pdf [Accessed 2012 Jan 13]
- 15.Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009; 195 (5 Suppl.): S13–9Google Scholar
- 17.European Medicines Agency. Paliperidone palmitate (Xeplion®): European public assessment report [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002105/WC500103370.pdf [Accessed 2011 Oct7]
- 18.European Medicines Agency. Invega® (paliperidone prolonged-release tablets): scientific discussion [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000746/WC500034928.pdf [Accessed 2012 Jan 9]
- 19.Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies [abstract no. PIII-57]. Clin Pharmacol Ther 2006 Feb; 79 (2): P74Google Scholar
- 24.Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuro-psychopharmacol 2010; 13 (5): 635–47Google Scholar
- 27.Schreiner A, Korcsog P, Niehaus D, et al. A prospective randomized controlled trial of paliperidone ER verus oral olanzapine in patients with schizophrenia [abstract]. Int Clin Psychopharmacol 2011 Sep; 26 e-Suppl. 1: e67-8Google Scholar
- 29.Cleton A, Rossenu S, Hough D, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles [abstract no. PI-74]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S31Google Scholar
- 32.Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010 Feb; 116 (2–3): 107–17Google Scholar
- 33.Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012; 15 (1): 107–118. Plus supplementary material available from URL: http://journals.cambridge.org/action/displayJournal?jid=PNP [Accessed 2012 Jan 17]CrossRefGoogle Scholar
- 34.Bossie CA, Sliwa JK, Ma Y-W, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 2011 May 10; 11: 79Google Scholar
- 35.Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011 Apr 11; 10: 12Google Scholar
- 43.Lundbeck Ltd. Depixol® (flupentixol decanoate) injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/1074/SPC/Depixol+Injection+and+Conc+Injection/ [Accessed 2012 Jan 17]
- 44.Sanofi-Aventis. Modecate® (fluphenazine decanoate) concentrate injection 100mg/mL: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/6955/SPC/Modecate+Concentrate+Injection+100mg+ml/ [Accessed 2012 Jan 17]
- 45.Janssen-Cilag Ltd. Haldol® decanoate (haloperidol decanoate) 50 and 100mg/mL: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/904/SPC/Haldol+Decanoate/ [Accessed 2012 Jan 17]
- 46.Sanofi-Aventis. Piportil® (pipotiazine palmitate) depot 50mg/mL solution for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/950/SPC/Piportil+Depot+Injection/ [Accessed 2012 Jan 17]
- 47.Lundbeck Ltd. Clopixol® (zuclopenthixol decanoate) solution for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/21319/SPC/Clopixol+Injection+and+Conc+Injection/ [Accessed 2012 Jan 17]
- 49.Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009 Nov; 195 (52): s63–7Google Scholar
- 50.Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195 (5 Suppl.): S29–36Google Scholar
- 51.Janssen-Cilag Ltd. Risperdal Consta (risperidone) powder and solvent for prolonged-release suspension for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/9939/SPC/RISPERDAL+CONSTA+25%2c+37.5+and+50+mg+powder+and+solvent+for+prolonged-release+suspension+for+intramuscular+injection/ [Accessed 2012 Jan 17]
- 52.Eli Lilly Nederland BV. Zypadhera (olanzapine pamoate) powder and solvent for prolonged release suspension for injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf [Accessed 2012 Jan 17]